A New Wave of Progress in Relapsed/Refractory Multiple Myeloma: Global Perspectives on Antibody-Based Treatment Strategies
Live, Interactive Webcast!
5:00 AM EST
11:00 AM CET
The treatment landscape for patients with multiple myeloma (MM) has evolved rapidly due to an enhanced understanding of the heterogeneous nature of the disease. As novel monoclonal antibody-based therapies emerge in the frontline and relapsed settings, clinicians are frequently unsure of how to interpret new data effectively, and how to appropriately combine and sequence therapies to improve patient outcomes.
A New Wave of Progress in Relapsed/Refractory Multiple Myeloma: Global Perspectives on Antibody-Based Treatment Strategies is a virtual symposium that will provide insights from experts on the topic in the form of didactic sessions and multidisciplinary case discussions. This activity will help health care professionals maintain a state-of-the-art clinical practice by providing updates on the latest clinical data on novel monoclonal antibody therapies in MM, and by offering expert guidance on combining and sequencing therapies.
Benefits of Attending
- Improve your knowledge of the mechanism of action, safety, and efficacy profiles of established and novel monoclonal antibodies for the treatment of MM
- Gain expert perspectives on data from recent combination trials investigating the role of monoclonal antibodies to treat relapsed/refractory MM
- Learn from the experts how to personalize treatment for relapsed/refractory MM based on patient risk stratification, prior therapeutic regimens, and other clinical considerations
- Sequencing Therapies in Relapsed/Refractory Multiple Myeloma
- Novel Antibody-Based Therapies in Multiple Myeloma
- Combination Treatment Strategies in Relapsed/Refractory Multiple Myeloma
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Sanofi Genzyme.
These activities are intended for medical oncologists and hematologists who treat patients with MM. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with MM are also invited to participate.
Upon completion of this activity, participants will be able to:
- Distinguish the mechanism of action and the safety, and efficacy profiles of established and novel monoclonal antibodies for the treatment of MM
- Summarize data from recent combination trials investigating the role of monoclonal antibodies to treat relapsed/refractory MM
- Individualize therapeutic strategies for relapsed/refractory MM based on patient risk stratification, prior therapeutics regimens, and other clinical considerations
Director, Clinical Research
Clinical Program Leader
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Professor of Hematology
Director, Cord Blood Bank and Unrelated Donor Registry
Director, Hematology Clinical Trials Unit
Consultant Haematologist NCCC
Newcastle Upon Tyne Hospital Trust
Professor of Clinical Haematology
University of Newcastle Upon Tyne
Newcastle Upon Tyne, England
Deputy Director and Associate Professor
Department of Oncology, Hematology and Bone Marrow Transplantation
Department of Pneumology
University Medical Center Hamburg-Eppendorf
Registration2 Ways to Register
- Online: click here.
- Phone: Please call (888) 949-0045 or (609) 378-3701
Physicians' Education Resource®
2 Clarke Drive
Cranbury, NJ 08512
Registration Fee - Free
For registration assistance, please email email@example.com, or call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.
Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.
By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.
Meeting information is accurate at the time of posting.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
You must be logged in to PER to register for this meeting
Or Register for PER now